Meeting
2012 ASCO Annual Meeting
Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.
Authors
Herlinde Dumez
Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
Herlinde Dumez , Andrea Gombos , Patrick Schöffski , Thierry Gil , Christof Vulsteke , Marie-Anne Meeus , Jessica Cescutti , Gerd Michael Munzert , Korinna Pilz , Ahmad Awada
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cell Cycle and Checkpoints
Clinical Trial Registration Number
NCT00969761
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3018^)
Abstract #
3018^
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2014 ASCO Annual Meeting
Pazopanib (P) and cisplatin (CDDP) in patients with advanced solid tumors: A UNICANCER phase I study.
First Author: Veronique Dieras
Poster
2013 ASCO Annual Meeting
A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors.
First Author: Filippo G. De Braud